Paolo Tarantino: Some HER2+ tumors melt upon dual anti-HER2 Treatment

Paolo Tarantino shared on X:

“Some HER2+ tumors melt upon dual anti-HER2 Treatment; others require chemo, or don’t respond to anything. Dissecting them, a key challenge with huge clinical impact. Find the latest understanding on anti-HER2 treatment tailoring in our latest article, led by Ada Waks.”

Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance | Nature Reviews Clinical Oncology 

Authors: Adrienne G. Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortés, Sara M. Tolaney and Aleix Prat

Source: Paolo Tarantino/X

More posts featuring Paolo Tarantino on oncodialy.com

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.